Introduction
Microarrays, as a multiplex immunoassay platform, have been used in the assessment of allergen specific-IgE (sIgE) for over the past 15 years. Wiltshire, et al. [1] prepared extracts of cat hair, dust mites and peanut, and then arrayed these onto an activated glass slide (microarray substrate). Sera with known levels of sIgE based upon Auto Cap (Pharmacia) values were applied. Detection of the sIgE on the microarrays was accomplished using ImmunoRCA (Rolling Circle Amplification) and the results compared to the CAP values. The microarray method was found to have a higher positive predictive value, higher specificity and in most cases greater sensitivity. Likewise, Kim, et al. [2] dispensed Martinez-Aranguren, et al. [7] evaluated the ImmunoCAP ISAC 112 chip kit comprising 5 slides with each slide containing 4 sub-arrays of 112 protein components covering 51 allergens. The validation study was based upon manufacturer's calibrators, as well as, sera obtained from 19 patients and included inter-assay, intra-assay and inter-lab analyses. The mean Coefficient of Variation (CV) for calibrators was 9.42%. The Intra-Class Coefficient Correlation (ICC) was used as a measure of reproducibility and repeatability. For inter-assay (reproducibility), determinations for IgE in 94/112 (83.9% of allergens) had very good reproducibility (ICC > 0.90), as was found for the reproducibility (intra-assay) of this set. The inter-laboratory agreement was very good for 73/112 allergens (ICC > 0.90) and good for 22 (ICC = 0.71-0.90). While the microarray performed well, there were several instances noted in which the expected values were not achieved leading the authors to conclude that, "due to the low accuracy obtained in some (reported 7-8 components) of the studied allergens, the application of this semi-quantitative technique for diagnosis in clinical situations where results may have a major impact on the therapy prescribed may not be advisable".
However, Moreira, et al. [8] evaluated sera of patients from Brazil having grass pollen allergy using ImmunoCAP ISAC microarrays. In their study, an ISAC chip containing 103 components was used that included 9 allergens for timothy grass pollen and 1 allergen for Bermuda grass. In this case, 77 of 78 patients tested positive for timothy grass pollen. Thus, these researchers suggest that the ISAC allergen microarray could be useful in diagnosis and immunotherapy monitoring for patients suffering from Brazilian grass pollens.
Studies on the development of microarrays in general and specifically for allergen testing have been largely based upon surface activated glass or nitrocellulose coated glass slide substrates. Micro plate-based microarray platforms are now commercially available and being adopted for multiplex immunoassays including allergy testing. The A 2 Microarray System (QuantiScientifics) is a multiplex quantitative immunoassay platform based upon a 96-well polypropylene plate to which proteins maybe tethered via an oligonucleotide bridge to create antibody or antigen microarrays. For example, Robbins, et al. [9] created an A 2 plate cytokine antibody array in order to measure the release of cytokines resulting from the immuno-stimulatory effects of lipid-delivered siRNAs in primary CD34+progenitor-derived hematopoietic cells.
Here, we examine the utility of the A 2 multiplex assay platform in the development of component-resolved diagnostics for allergens based upon oligonucleotide tethering of allergenic proteins. In these studies, we use both purified milk protein allergens and crude extracts as a model [10] .
Materials and Methods
The following reagents were obtained from QuantiScientifics 
Proteins
Cow's milk derived proteins were obtained in purified form from Sigma-Aldrich (see Table 1 ). Streptavidin-alkaline phosphates conjugate (Thermo Scientific, Pierce # 21324); Goat anti-human IgE alkaline phosphatase conjugates (Sigma-Aldrich, A3525).
Serum Samples: Hycor Biomedical (Garden Grove, CA) provided milk allergenic positive patient sera and spiked control sera for evaluation.
Preparation of oligonucleotide-protein conjugates
2OD 260nm units of an SMCC (4-(N-maleimidomethyl) cyclohexane-1-carboxylic acid N-hydroxysuccinimidyl) activated oligonucleotide are reacted with 100 µg of purified protein.
The process involves adsorption (hydrophobic interaction) of the protein onto a solid-phase held within a spin-column. Next, initiator is added to modify the protein with reactive sulfhydryl (-SH) groups. Finally, the SMCC-oligonucleotide is added which covalently couples to the thiolate protein to form the oligoprotein conjugate. The resulting conjugate still bound to the solid-support is rinsed free of reactants; and subsequently eluted in purified form from the column ready for use.
Preparation of oligo-F2 (1) β-Lacto globulin conjugate from purified protein
Protein modification: 100 µL Butyl-Sepharose 4 Fast Flow (GE Healthcare Bio-Sciences AB, Uppsala, Sweden) was placed in a fritted spin column to achieve a compressed bed volume of 0.1 mL. The column was centrifuged at 2000 rpm for 30 seconds to remove liquid.
The resin was re-suspended in 600 µL of deionized water using a pipette; and the column washed by centrifugation. The centrifugation-rinse process was repeated, followed by 2 rinses in binding buffer.
Following the equilibration in binding buffer, the bottom of the column was carefully sealed with a cap. 600 µL of binding buffer was used to re-suspend the resin. Then, 50 µL = 100 µg of β-Lacto globulin (Sigma-Aldrich, L3908, MW 18,300 Daltons) from stock solution of 2 mg/ mL in TBST buffer was added. The resin was then mixed by Pipetting up & down and column recapped.
Following end-to-end tumbling of the column for 10 minutes, the caps were removed and the column centrifuged to remove the solution. 700 µL of freshly prepared protein activator solution (Iminothiolane Hydrochloride, Sigma-Aldrich, 16256) was added to the column bed; and the resin re-suspended. The column was capped and then mixed by tumbling for 1 hour.
The caps were then removed and the column centrifuged and the bed re-suspended, then rinsed 6 times with binding buffer as previously described.
Finally, 600 µL of fresh binding buffer was added, the column bottom capped and the resin re-suspended.
Coupling of the oligonucleotide to thiol-protein
100 µL of SMCC-oligo (2 ODs) prepared in binding buffer was added and the resin re-suspended and column capped. The spincolumn was mixed by tumbling for 24 hours at room temperature.
Following removal of the solution, the column was rinsed 5 times in binding buffer in order to remove reactants.
Elution of the oligo-protein conjugate
The column was then placed in a clean 1.5-mL Eppendorf micro-centrifuge tube for collection of the conjugate. 100 µL of elution buffer was added to the column with gentle mixing to re-suspend the resin. The column was incubated for 3 minutes and then centrifuged. The eluted fraction was collected as the source of the conjugate.
This process was repeated 4 more times with the collection of 100 µL fractions in separate tubes for a total of 5 fractions (500 µL).
The eluted fractions were combined and the solution stored at 4°C prior to use.
Preparation of the oligo-F2 (2); -F2 (3); -F2 (4); -F2 (5); -F2 (6); -F2 (7) and -F2 (8) conjugates
Additional milk proteins, F2 crude extract, as well as, the goat anti-Human IgE were conjugated to SMCC-oligonucleotides as described in the previous section detailing the preparation of oligo-F2 (1) conjugate. The assignments regarding choice of oligo used in coupling are provided in Table 1 . The selected Placement Table 1 . Component specific IgE (sIgE) in serum samples (S1 to S13) determined using the A 2 Multiplex Immunoassay. Mean Fluorescent Intensity (MFI) signal values obtained from the microarray spots were converted to International Units (IU) based upon the IgE standard curve (MFI vs. IU/ mL) provided in Figure 3 . Values ≤ 0.35 IU/mL are reported for indication only as a Minimal Detectable Dose (MDD). Table 1. within the array well are for format I (Figure 1 ) or array format II (Figure 2) .
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Preparation of the microplate microarray with oligonucleotide-tethered milk allergens
The oligo-protein conjugates were pooled in hybridization buffer at 2 µg/mL of each for application to the A2 capture oligo plate. Following a 5 minute soak and rinse of the plate wells with 3 x 200 µL TBST, 55 µL of the oligo-protein hybridization cocktail was delivered to each well using a pipette. The plate was incubated at ambient temperature with shaking for 1 hour. The wells were rinsed 3-times in TBST in preparation of the immunoassay.
Development of the multiplex allergen immunoassay
Serum samples (1-13) containing sIgE, negative control serum without IgE, and reference control sera containing varying amounts of IgE (0.35 IU/mL to 100 IU/mL) as standards (1 IU = 2.44 ng), as well as, the biotinylated reference oligo (fiducial) were delivered to wells of the microplate at 55 µL per well. The plate was incubated for 1 hour with shaking. Following TBST buffer rinse, a secondary antibody-alkaline phosphates conjugate (goat anti-human IgE) was applied in buffer at 55 µL per well. Reference fiducials of the biotinylated oligo were detected by the addition of streptavidin alkaline phosphatase to the mix. The plate was incubated for 1 hour with shaking, and then extensively rinsed in buffer. Next, 55 µL of AP Enzyme Substrate was added to each well. The plate was covered with foil and incubated for 30 minutes without shaking. The solution was carefully removed to semi-dry but not rinsed. 200 µL of fresh buffer was added to the developed plate and the plate scanned using the A2 Reader. Note: the proprietary enzyme substrate forms a fluorescent precipitate (similar to the tyramide signal amplification process) which is detected at 535 nm.
Analysis
An ELISA standard curve (Figure 3 , 4PL2 plot, AssayFit, IVDtools, Inc. Nijmegen, The Netherlands) was generated from serial dilution of the reference control sera. Fitted Curve:Response (MFI, mean fluorescent intensity) vs. Dose (Human IgE, IU/ mL). The IgE content in serum samples, negative serum and buffer was calculated from the curve. The A 2 Microarray System reader reports in pg/ mL units. Conversion to International Units (IU) was made based upon: 1 IU/ mL IgE = 2.44 ng/ mL = 2440 pg/ mL.
Results
The total IgE as measured from signal on arrayed spots (Figure 4 ) containing oligo-gt anti IgE was comparable across both well array formats (r = 0.9764), Figure 5 .
Likewise, signal (MFI) corresponding to sIgE was obtained for all samples. Negative control serum (MFI = 337 ± 67) and buffer blank (MFI= 259 ± 53) values were used to establish a cut- off baseline for non-specific binding at MFI = 538 corresponding to the negative control, MFI+3SD. In this study, the lowest IgE control used was 0.35 IU/mL yielding a signal, MFI = 1249 or about 2.3-fold above the cut-off value. Using the baseline cutoff, the identity and level of the principal "allergenic" component present in each sample could be more easily recognized in a composite profile (Figure 6 ).
Array I wells detected the presence or absence of sIgE in sera for immunological response to cow's milk proteins, principal components: F2-1 (β-lactoglobulin), F2-2 (α-lactalbumin), immunoglobulin G (IgG), and Bovine Serum Albumin (BSA). Spots containing immobilized goat anti-human IgE were used to estimate total IgE content in the sample. Very high levels (> 200,000 pg/mL or 200 ng/mL ~ 82 IU/mL) of total IgE were found in samples #3, #7, #9 and #11. These particular samples exhibited very low or non-detectable levels of sIgE (Figure 7) . In comparison, samples #6 and #12, while exhibiting low total IgE levels were found to contain mostly sIgE. Sample #6 contained sIgE toward F2-1, F2-2, F2-3 and F2-4; while sample #12 was prominent for F2-1 (Figure 8 , β-lactoglobulin) and F2-2.
From Array II, sample #1 was predominate for F2-5 ( Figure  9 , lactoferrin), while sample #13 contained modest amounts of sIgE for F2-7 (β-casein) and F2-8 (r-casein). Samples #2, #6, #9, #12 and #13 had detectable levels of F2-6 (αS-casein) above background. Coupling of oligonucleotide (QS17) to a crude milk protein extract was achieved providing the signal profiling sIgE's in serum samples but with a lowered response ( Figure 10 ).
A summary of the estimated content of specific IgE in the patient serum samples in provided in Table 2 . Values ≤ 0.35 IU/
Discussion
The A 2 Microarray technology is an open platform based upon a pre-printed and fixed pattern (microarray) of capture oligonucleotides in a 96-well micro plate, the A 2 Plate. Multiplex ELISAs once designed by the end-user are constructed using the complementary oligo linked to the selected proteins. A mixture of different oligo-proteins may then be hybridized to the microarray to create a protein array. For example, the tethering of oligo-antibody to form an antibody array is the primary application for this technology platform. Since, hybridization is a thermodynamically driven; self-assembly process the number of oligo/oligo-protein hybrids formed on the surface is limited and relatively constant. This results in improved spot uniformity within the array and reduces the variability commonly found with direct printing of proteins. Moreover, the oligo-protein conjugates are reagents that can be stored separately and combined as needed to create different plate assays upon demand.
Allergens represent a complex mixture of proteins and other biomolecules. It is most often difficult to resolve those proteins that are associated with a particular "allergenic" response. Because of such complexity, as well as, the vast number of allergens present in our environment it remains an arduous task in diagnosis. Thus, the well-known skin patch test based upon the use of allergen extracts is still prevalent even though a migration and adoption of the immunoassay has been underway for several decades. As previously discussed in the introduction, the development of immunoassays has progressed from e.g. the use of the Radio Allegro Sorbent Test (RAST), to performing a sIgE ELISA using slides or micro plates of printed extracts, to the use of automated diagnostic platforms such as ImmunoCAP or the ImmunoCAP ISAC for component resolved diagnostic platforms that were developed by Phadia (now part of Thermo Fisher Scientific).
In this study, we examined the potential use of the A 2 multiplex ELISA in the development of a component resolved methodology for detection of food-based allergens based upon determination of sIgE. Milk allergy was selected as a model because the allergy is prevalent, and the component proteins are readily available in purified form from commercial sources.
The oligo-protein conjugates were successfully prepared, assembled onto the microarray and the IgE ELISA demonstrated. The A 2 multiplex ELISA was used to quantify both total IgE and
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Copyright: © 2016 Matson sIgE in serum samples over the range of 0.35 -100 IU/mL In addition to evaluating conjugates of component proteins, the study included a conjugate prepared from the crude milk allergen extract. A profile (Figure 10 ) of milk allergen content (sIgE) across the serum samples was obtained, albeit at reduced signal intensity relative to individual component proteins. Moreover, it was possible to partially reconstruct the profile (Figure 11) by summation of the sIgE content (IU/ mL) of the major component proteins found in each sample listed in Table 2 . This provides a further validation that the observed IgE levels detected using the oligo-tethered crude extract reflect the relative contribution of the individual component protein IgE response within the sample.
In summary, this model study demonstrates that oligonucleotide-tethering of proteins of broad molecular weight range (10,000 to 150,000 Daltons) and diverse physical-chemical properties are possible using the A 2 technology. Moreover, the microarray bound oligo-allergens were found to be accessible to interaction with serum sIgE allowing the development of a multiplex immunoassay for milk allergens. The A2 multiplex ELISA permitted screening for sIgE using an oligo-tethered milk allergen extract, as well as, quantitation of component specific IgEand total IgE content of the sample within the same well.
